Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease

Hossein Jadvar, Patrick M. Colletti, Roberto Delgado-Bolton, Giuseppe Esposito, Bernd J. Krause, Andrei H. Iagaru, Helen Nadel, David I. Quinn, Eric Rohren, Rathan M. Subramaniam, Katherine Zukotynski, Julie Kauffman, Sukhjeet Ahuja, Landis Griffeth

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Precision medicine is evolving to include a variety of data to optimize patient care and improve outcome. Multimodality imaging is paving the way toward this goal. PET/CT with 18F-FDG is now established as an important imaging modality in many clinical conditions, particularly in oncology (1,2). Many tumors demonstrate high glucose metabolism as one of the hallmarks of cancer (3). PET/CT provides combined anatomic and physiologic (glucose metabolism) information that may be used for initial diagnosis, staging, restaging, treatment response assessment, and prognosis in patients with cancer. Moreover, PET information can contribute significantly when other imaging modalities are equivocal. This document describes the appropriate use of PET/CT∗ in the response assessment and restaging of patients with cancer. Our focus is on common cancers in which the use of PET/CT has been most relevant for clinical practice. Restaging is broadly defined to include the phase of the disease after initial diagnosis and treatment, which may entail local recurrence, distant metastatic disease, and assessment of response to treatments after disease recurrence. The goal of these recommendations is to guide the appropriate use of PET/CT in assessing treatment response after therapy and in evaluating imaging of patients with suspected recurrent cancer. Although the terms response assessment and restaging are frequently used in the discussion of cancer treatment, no consensus definition exists regarding the time frame that differentiates these 2 terms. Indeed, the time interval at which a patient transitions from response assessment to restaging likely varies in relation to tumor biology, therapeutic regimen, and other factors. In this work, the term assessment of response is taken to mean the period in which the intended target of the therapeutic regimen is being evaluated, whereas the term restaging of disease is taken to mean the period in which there is concern for new or progressive disease after completion of prior therapy. This document excludes "initial staging" and "surveillance." These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of PET/CT for restaging of breast cancer, colorectal cancer, lymphoma, lung cancer, melanoma, sarcoma, and head and neck cancer.

Original languageEnglish (US)
Pages (from-to)2026-2037
Number of pages12
JournalJournal of Nuclear Medicine
Volume58
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Fluorodeoxyglucose F18
Neoplasms
Therapeutics
Lung Neoplasms
Glucose
Recurrence
Patient Transfer
Precision Medicine
Head and Neck Neoplasms
Sarcoma
Colorectal Neoplasms
Melanoma
Lymphoma
Patient Care
Breast Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Jadvar, H., Colletti, P. M., Delgado-Bolton, R., Esposito, G., Krause, B. J., Iagaru, A. H., ... Griffeth, L. (2017). Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. Journal of Nuclear Medicine, 58(12), 2026-2037. https://doi.org/10.2967/jnumed.117.197988

Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. / Jadvar, Hossein; Colletti, Patrick M.; Delgado-Bolton, Roberto; Esposito, Giuseppe; Krause, Bernd J.; Iagaru, Andrei H.; Nadel, Helen; Quinn, David I.; Rohren, Eric; Subramaniam, Rathan M.; Zukotynski, Katherine; Kauffman, Julie; Ahuja, Sukhjeet; Griffeth, Landis.

In: Journal of Nuclear Medicine, Vol. 58, No. 12, 01.12.2017, p. 2026-2037.

Research output: Contribution to journalArticle

Jadvar, H, Colletti, PM, Delgado-Bolton, R, Esposito, G, Krause, BJ, Iagaru, AH, Nadel, H, Quinn, DI, Rohren, E, Subramaniam, RM, Zukotynski, K, Kauffman, J, Ahuja, S & Griffeth, L 2017, 'Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease', Journal of Nuclear Medicine, vol. 58, no. 12, pp. 2026-2037. https://doi.org/10.2967/jnumed.117.197988
Jadvar, Hossein ; Colletti, Patrick M. ; Delgado-Bolton, Roberto ; Esposito, Giuseppe ; Krause, Bernd J. ; Iagaru, Andrei H. ; Nadel, Helen ; Quinn, David I. ; Rohren, Eric ; Subramaniam, Rathan M. ; Zukotynski, Katherine ; Kauffman, Julie ; Ahuja, Sukhjeet ; Griffeth, Landis. / Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. In: Journal of Nuclear Medicine. 2017 ; Vol. 58, No. 12. pp. 2026-2037.
@article{2b61f96d93bf426588919542b3ea6600,
title = "Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease",
abstract = "Precision medicine is evolving to include a variety of data to optimize patient care and improve outcome. Multimodality imaging is paving the way toward this goal. PET/CT with 18F-FDG is now established as an important imaging modality in many clinical conditions, particularly in oncology (1,2). Many tumors demonstrate high glucose metabolism as one of the hallmarks of cancer (3). PET/CT provides combined anatomic and physiologic (glucose metabolism) information that may be used for initial diagnosis, staging, restaging, treatment response assessment, and prognosis in patients with cancer. Moreover, PET information can contribute significantly when other imaging modalities are equivocal. This document describes the appropriate use of PET/CT∗ in the response assessment and restaging of patients with cancer. Our focus is on common cancers in which the use of PET/CT has been most relevant for clinical practice. Restaging is broadly defined to include the phase of the disease after initial diagnosis and treatment, which may entail local recurrence, distant metastatic disease, and assessment of response to treatments after disease recurrence. The goal of these recommendations is to guide the appropriate use of PET/CT in assessing treatment response after therapy and in evaluating imaging of patients with suspected recurrent cancer. Although the terms response assessment and restaging are frequently used in the discussion of cancer treatment, no consensus definition exists regarding the time frame that differentiates these 2 terms. Indeed, the time interval at which a patient transitions from response assessment to restaging likely varies in relation to tumor biology, therapeutic regimen, and other factors. In this work, the term assessment of response is taken to mean the period in which the intended target of the therapeutic regimen is being evaluated, whereas the term restaging of disease is taken to mean the period in which there is concern for new or progressive disease after completion of prior therapy. This document excludes {"}initial staging{"} and {"}surveillance.{"} These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of PET/CT for restaging of breast cancer, colorectal cancer, lymphoma, lung cancer, melanoma, sarcoma, and head and neck cancer.",
author = "Hossein Jadvar and Colletti, {Patrick M.} and Roberto Delgado-Bolton and Giuseppe Esposito and Krause, {Bernd J.} and Iagaru, {Andrei H.} and Helen Nadel and Quinn, {David I.} and Eric Rohren and Subramaniam, {Rathan M.} and Katherine Zukotynski and Julie Kauffman and Sukhjeet Ahuja and Landis Griffeth",
year = "2017",
month = "12",
day = "1",
doi = "10.2967/jnumed.117.197988",
language = "English (US)",
volume = "58",
pages = "2026--2037",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "12",

}

TY - JOUR

T1 - Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease

AU - Jadvar, Hossein

AU - Colletti, Patrick M.

AU - Delgado-Bolton, Roberto

AU - Esposito, Giuseppe

AU - Krause, Bernd J.

AU - Iagaru, Andrei H.

AU - Nadel, Helen

AU - Quinn, David I.

AU - Rohren, Eric

AU - Subramaniam, Rathan M.

AU - Zukotynski, Katherine

AU - Kauffman, Julie

AU - Ahuja, Sukhjeet

AU - Griffeth, Landis

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Precision medicine is evolving to include a variety of data to optimize patient care and improve outcome. Multimodality imaging is paving the way toward this goal. PET/CT with 18F-FDG is now established as an important imaging modality in many clinical conditions, particularly in oncology (1,2). Many tumors demonstrate high glucose metabolism as one of the hallmarks of cancer (3). PET/CT provides combined anatomic and physiologic (glucose metabolism) information that may be used for initial diagnosis, staging, restaging, treatment response assessment, and prognosis in patients with cancer. Moreover, PET information can contribute significantly when other imaging modalities are equivocal. This document describes the appropriate use of PET/CT∗ in the response assessment and restaging of patients with cancer. Our focus is on common cancers in which the use of PET/CT has been most relevant for clinical practice. Restaging is broadly defined to include the phase of the disease after initial diagnosis and treatment, which may entail local recurrence, distant metastatic disease, and assessment of response to treatments after disease recurrence. The goal of these recommendations is to guide the appropriate use of PET/CT in assessing treatment response after therapy and in evaluating imaging of patients with suspected recurrent cancer. Although the terms response assessment and restaging are frequently used in the discussion of cancer treatment, no consensus definition exists regarding the time frame that differentiates these 2 terms. Indeed, the time interval at which a patient transitions from response assessment to restaging likely varies in relation to tumor biology, therapeutic regimen, and other factors. In this work, the term assessment of response is taken to mean the period in which the intended target of the therapeutic regimen is being evaluated, whereas the term restaging of disease is taken to mean the period in which there is concern for new or progressive disease after completion of prior therapy. This document excludes "initial staging" and "surveillance." These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of PET/CT for restaging of breast cancer, colorectal cancer, lymphoma, lung cancer, melanoma, sarcoma, and head and neck cancer.

AB - Precision medicine is evolving to include a variety of data to optimize patient care and improve outcome. Multimodality imaging is paving the way toward this goal. PET/CT with 18F-FDG is now established as an important imaging modality in many clinical conditions, particularly in oncology (1,2). Many tumors demonstrate high glucose metabolism as one of the hallmarks of cancer (3). PET/CT provides combined anatomic and physiologic (glucose metabolism) information that may be used for initial diagnosis, staging, restaging, treatment response assessment, and prognosis in patients with cancer. Moreover, PET information can contribute significantly when other imaging modalities are equivocal. This document describes the appropriate use of PET/CT∗ in the response assessment and restaging of patients with cancer. Our focus is on common cancers in which the use of PET/CT has been most relevant for clinical practice. Restaging is broadly defined to include the phase of the disease after initial diagnosis and treatment, which may entail local recurrence, distant metastatic disease, and assessment of response to treatments after disease recurrence. The goal of these recommendations is to guide the appropriate use of PET/CT in assessing treatment response after therapy and in evaluating imaging of patients with suspected recurrent cancer. Although the terms response assessment and restaging are frequently used in the discussion of cancer treatment, no consensus definition exists regarding the time frame that differentiates these 2 terms. Indeed, the time interval at which a patient transitions from response assessment to restaging likely varies in relation to tumor biology, therapeutic regimen, and other factors. In this work, the term assessment of response is taken to mean the period in which the intended target of the therapeutic regimen is being evaluated, whereas the term restaging of disease is taken to mean the period in which there is concern for new or progressive disease after completion of prior therapy. This document excludes "initial staging" and "surveillance." These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of PET/CT for restaging of breast cancer, colorectal cancer, lymphoma, lung cancer, melanoma, sarcoma, and head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=85037143689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037143689&partnerID=8YFLogxK

U2 - 10.2967/jnumed.117.197988

DO - 10.2967/jnumed.117.197988

M3 - Article

C2 - 29025980

AN - SCOPUS:85037143689

VL - 58

SP - 2026

EP - 2037

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 12

ER -